RTHawk Research
MRI operating system and GUI-based design tools for creating custom imaging applications
Company profile
Company profile
Vista AI develops intelligent software to streamline and automate MRI examinations, making gold-standard imaging universally accessible. The company's flagship product, Vista AI Scan, is an FDA-cleared automated scanning platform that began with Cardiac MRI (CMR)—the most complex and underserved MRI exam—and is expanding to brain, prostate, spine, and other anatomical areas. Founded by Stanford-trained imaging experts, Vista AI addresses critical healthcare challenges including rising demand, staffing shortages, and increasing clinical complexity in imaging programs. The platform enables existing MRI technologists to perform complex scans that previously required specialists, standardizing imaging quality across technologists and locations while boosting throughput with existing resources. Vista AI Scan has demonstrated real-world results including 26% faster CMR scan times, 50% more scan slots, and reduction of scan backlogs from 28 days to 1-day access. The company serves health systems and imaging centers, helping them expand services, reduce patient leakage to competitors, and deliver earlier diagnosis and timely treatment. Vista AI also offers RTHawk Research, a platform for academic and research institutions to develop advanced MRI applications with graphical pulse sequence design tools, advanced reconstruction capabilities, and real-time feedback integration. Backed by Khosla Ventures and guided by leading medical advisors from Stanford Medicine and University of Wisconsin-Madison, Vista AI is scaling its automation platform to transform how MRI imaging is delivered across healthcare systems.
Company description Vista AI official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Embedded · On Premise deployment with recorded integration context.
Company milestones
Two-year clinical data published December 2024. Daniel Hawkins appointed CEO March 2024. Steve Cashman joined Board of Directors September 2023. FDA clearance obtained for Vista AI Scan.
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
MRI operating system and GUI-based design tools for creating custom imaging applications
FDA-cleared automated Cardiac MRI scanning software for consistent, high-quality imaging
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
JACC. Advances · Apr 1, 2026
Free-breathing 3D pulmonary ventilation mapping at 0.55 T using stack-of-spiral out-in bSSFP.Magnetic resonance in medicine · Jan 1, 2026
A pharmacokinetic model for hyperpolarized 13C-pyruvate MRI when using metabolite-specific bSSFP sequences.Magnetic resonance in medicine · Oct 1, 2024
Regional quantification of cardiac metabolism with hyperpolarized [1-13C]-pyruvate CMR evaluated in an oral glucose challenge.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · Dec 14, 2023
Regional quantification of cardiac metabolism with hyperpolarized [1-13C]-pyruvate MRI evaluated in an oral glucose challenge.medRxiv : the preprint server for health sciences · Oct 19, 2023
A metabolite specific 3D stack-of-spirals bSSFP sequence for improved bicarbonate imaging in hyperpolarized [1-13C]Pyruvate MRI.Journal of magnetic resonance (San Diego, Calif. : 1997) · Aug 1, 2023
Clinical validation
No linked records are currently available.
Regulatory
K251029 · 510k · Aug 21, 2025
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Real-world clinical deployment
Increased throughput with existing resources
Reduction in patient wait times
Enhancing MRI workflow efficiency and consistency while reducing training time and errors
Faster scanning with greater confidence, quicker technologist training, reduced errors, increased productivity and patient access
Increasing access to high-quality cardiac MRI throughout the community
Improved quality of cardiac MR imaging across the board
MRI research applications including catheter tracking and real-time analysis of movement
Successful implementation of advanced MRI research applications
MR-guided EP Ablation research
Successful research implementation using RTHawk Research platform
Reducing cardiac MRI backlog and improving scan access
26% faster CMR scan times, 50% more scan slots, 1-day CMR access from a 28-day backlog
MR-guided Convection Enhanced Delivery research
Successful research implementation using RTHawk Research platform
05 · Leadership
Leadership profiles and professional links from the current Company record.
Daniel Hawkins
President and CEO
Bob Hu
Chief Medical Officer and Co-Founder
Juan Santos
Chief Architect and Head of Research and Co-Founder
William Overall
Chief Technology Officer and Co-Founder
Nicole Winokur
Vice President of Marketing
Sheila Saldana
Vice President of Client Success
06 · Company updates
Recent articles published on Vista AI's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.